AbCellera Biologics 正式对外披露,其总额达2亿美元、涉及普通股及预融资权证的公开发行项目已获超额认购,并完成最终定价。
AbCellera Biologics 正式对外披露,其总额达2亿美元、涉及普通股及预融资权证的公开发行项目已获超额认购,并完成最终定价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.